Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III trial of remimazolam sedation for gastrointestinal endoscopy in Japanese patients
jRCT2031200360Phase 3Completed
- Sponsor
- Mundipharma
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of remimazolam (5 arms), sponsored by Mundipharma. Primary endpoint: Success rate of sedation in gastrointestinal endoscopy. Started May 2021; status: completed.
02
Drugs
remimazolam
Beyond the preview
Go deeper on jRCT2031200360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200360.